Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/MM Fusion Vaccine and BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07377435Phase 1Recruiting
- Sponsor
- David Avigan
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dendritic cell-myeloma fusion vaccine in multiple myeloma (MM), sponsored by David Avigan. Primary endpoints: Treatment Limiting Toxicity Rate at 28 days, Vaccine/GM-CSF-Related Adverse Event Rate at 1 year and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
dendritic cell-myeloma fusion vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07377435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377435.